creators_name: Ding, C
creators_name: Jones, G
creators_id: chding@utas.edu.au
creators_id: 
type: article
datestamp: 2008-04-07 01:36:07
lastmod: 2008-07-18 10:43:13
metadata_visibility: show
title: Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline)
ispublished: pub
subjects: 320503
full_text_status: restricted
note: restricted - published by Thompson
abstract: Belimumab, the lead in a series of human monoclonal antibodies against the human protein B-lymphocyte stimulator (BLyS), is under development by Human Genome Sciences, Cambridge Antibody Technology and GlaxoSmithKline for the potential treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). By January 2006, belimumab had completed phase II clinical trials in SLE and RA; a phase III clinical SLE trial is scheduled to begin later this year.
date: 2006
date_type: published
publication: Current Opinion in Investigational Drugs
volume: 7
number: 5
pagerange: 464-472
refereed: TRUE
issn: 1472-4472
official_url: http://www.biomedcentral.com/1472-4472/7?issue=5
citation: Ding, C and Jones, G (2006) Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline). Current Opinion in Investigational Drugs, 7 (5). pp. 464-472. ISSN 1472-4472
document_url: http://eprints.utas.edu.au/3609/1/belimumab.pdf